Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.
General Material Designation
[Book]
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Geneva :
Name of Publisher, Distributor, etc.
Distributed by WHO Press,
Date of Publication, Distribution, etc.
2007.
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
1 online resource (ix, 528 pages) :
Other Physical Details
illustrations
SERIES
Series Title
IARC monographs on the evaluation of carcinogenic risks to humans ;
Volume Designation
v. 91
GENERAL NOTES
Text of Note
"This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 7-14 June 2005."
Text of Note
At head of title: World Health Organization, International Agency for Research on Cancer.
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and cumulative index.
CONTENTS NOTE
Text of Note
Preliminaries; CONTENTS; PREAMBLE; Combined Estrogen-Progestogen Contraceptives; Combined Estrogen-Progestogen Menopausal Therapy; ANNEXES; CUMULATIVE INDEX TO THE MONOGRAPHS SERIES
0
SUMMARY OR ABSTRACT
Text of Note
Oral contraceptives for family planning worldwide have revolutionized the reproductive lives of millions of women since their introduction in the 1960s. Later on, a variety of side-effects including cardiovascular diseases was recognized. In response to these concerns, new generations of combined oral contraceptives were developed that featured lower dose of estrogen and newer, more potent progestogens. The effectiveness and ease of use of combined hormonal contraceptives suggest that they will continue to be used to a significant extent in the future. This ninety-first volume of IARC Monograp.
OTHER EDITION IN ANOTHER MEDIUM
Title
Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.
International Standard Book Number
9283212916
TOPICAL NAME USED AS SUBJECT
Cancer-- Risk factors.
Catechol estrogens-- Carcinogenicity.
Catechol estrogens-- Side effects.
Chemical carcinogenesis.
Contraception-- Complications.
Estrogen-- Carcinogenicity.
Estrogen-- Side effects.
Menopause-- Hormone therapy-- Complications.
Oral contraceptives-- Carcinogenicity.
Progestational hormones-- Carcinogenicity.
Progestational hormones-- Side effects.
Women-- Diseases-- Risk factors.
Carcinogens.
Contraceptives, Oral, Combined-- adverse effects.
Contraceptives, Oral, Hormonal-- adverse effects.
Estrogens-- adverse effects.
Estrogens-- therapeutic use.
Hormone Replacement Therapy-- adverse effects.
Neoplasms-- chemically induced.
Neoplasms-- prevention & control.
Progestins-- adverse effects.
Progestins-- therapeutic use.
Cancer-- Risk factors.
Chemical carcinogenesis.
Contraception-- Complications.
HEALTH & FITNESS-- Diseases-- Cancer.
MEDICAL-- Oncology.
Menopause-- Hormone therapy-- Complications.
Oral contraceptives-- Carcinogenicity.
(SUBJECT CATEGORY (Provisional
HEA-- 039030
MED-- 062000
DEWEY DECIMAL CLASSIFICATION
Number
616
.
994071
Edition
22
LIBRARY OF CONGRESS CLASSIFICATION
Class number
RC268
.
7
.
O72
Book number
I19
2007eb
OTHER CLASS NUMBERS
Class number
QZ
202
Class number
W1
Book Number
I103c
2007
Book Number
IA21I
v
.
91
2007
CORPORATE BODY NAME - PRIMARY RESPONSIBILITY
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans(2005 :, Lyon, France)